• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
Logo of jnnpsycJournal of Neurology, Neurosurgery and PsychiatryCurrent TOCInstructions for authors
J Neurol Neurosurg Psychiatry. Aug 1994; 57(8): 903–910.
PMCID: PMC1073071

The Sydney Multicentre Study of Parkinson's disease: a randomised, prospective five year study comparing low dose bromocriptine with low dose levodopa-carbidopa.

Abstract

149 previously untreated patients with Parkinson's disease were recruited over a three year period and randomly allocated to either low dose levodopa-carbidopa (< or = 600/150 mg/day) or low dose bromocriptine (< or = 30 mg/day). A five year follow up is reported on the 126 patients who completed the dose titration and who have not developed features of atypical Parkinsonism. Levodopa-carbidopa in low dosage adequately controlled symptoms in most patients and delayed the appearance of dyskinesia and end of dose failure for about two years longer than conventional doses. Only a few patients could be managed for more than one year on low dose bromocriptine alone; these patients had mild disease and asymmetric signs. Patients randomised to bromocriptine did not develop dyskinesia or troublesome end of dose failure until levodopa-carbidopa was added. The prevalence of dyskinesia in this group was lower than in patients given levodopa-carbidopa alone. The prevalence of end of dose failure was similar in the two randomisation groups once levodopa was introduced.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (1.4M), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Hely MA, Morris JG, Rail D, Reid WG, O'Sullivan DJ, Williamson PM, Genge S, Broe GA. The Sydney Multicentre Study of Parkinson's disease: a report on the first 3 years. J Neurol Neurosurg Psychiatry. 1989 Mar;52(3):324–328. [PMC free article] [PubMed]
  • Calne DB, Teychenne PF, Claveria LE, Eastman R, Greenacre JK, Petrie A. Bromocriptine in Parkinsonism. Br Med J. 1974 Nov 23;4(5942):442–444. [PMC free article] [PubMed]
  • Aellig WH, Nüesch E. Comparative pharmacokinetic investigations with tritium-labeled ergot alkaloids after oral and intravenous administration man. Int J Clin Pharmacol Biopharm. 1977 Mar;15(3):106–112. [PubMed]
  • Parkes JD, Debono AG, Marsden CD. Bromocriptine in Parkinsonism: long-term treatment, dose response, and comparison with levodopa. J Neurol Neurosurg Psychiatry. 1976 Nov;39(11):1101–1108. [PMC free article] [PubMed]
  • Stern GM, Lees AJ. Sustained bromocriptine therapy in 50 previously untreated patients with Parkinson's disease. Adv Neurol. 1983;37:17–21. [PubMed]
  • Bergamasco B, Benna P, Scarzella L. Long-term bromocriptine treatment of de novo patients with Parkinson's disease. A seven-year follow-up. Acta Neurol Scand. 1990 May;81(5):383–387. [PubMed]
  • Teychenne PF, Bergsrud D, Racy A, Elton RL, Vern B. Bromocriptine: low-dose therapy in Parkinson disease. Neurology. 1982 Jun;32(6):577–583. [PubMed]
  • Rinne UK. Combined bromocriptine-levodopa therapy early in Parkinson's disease. Neurology. 1985 Aug;35(8):1196–1198. [PubMed]
  • Lieberman A. Dopamine agonists used as monotherapy in de novo PD patients: comparisons with selegiline. Neurology. 1992 Apr;42(4 Suppl 4):37–48. [PubMed]
  • Hely MA, Chey T, Wilson A, Williamson PM, O'Sullivan DJ, Rail D, Morris JG. Reliability of the Columbia scale for assessing signs of Parkinson's disease. Mov Disord. 1993 Oct;8(4):466–472. [PubMed]
  • CANTER GJ, DE LA TORRE R, MIER M. A method for evaluating disability in patients with Parkinson's disease. J Nerv Ment Dis. 1961 Aug;133:143–147. [PubMed]
  • Hofmann WW, Angel RW. Transient responses of the normal and diseased motor system to sudden load changes. Neurology. 1967 Oct;17(10):952–960. [PubMed]
  • Prentice RL, Marek P. A qualitative discrepancy between censored data rank tests. Biometrics. 1979 Dec;35(4):861–867. [PubMed]
  • Reid WG, Broe GA, Hely MA, Morris JG, Williamson PM, O'Sullivan DJ, Rail D, Genge S, Moss NG. The neuropsychology of de novo patients with idiopathic Parkinson's disease: the effects of age of onset. Int J Neurosci. 1989 Oct;48(3-4):205–217. [PubMed]
  • Boshes B. Sinemet and the treatment of Parkinsonism. Ann Intern Med. 1981 Mar;94(3):364–370. [PubMed]
  • Shaw KM, Lees AJ, Stern GM. The impact of treatment with levodopa on Parkinson's disease. Q J Med. 1980;49(195):283–293. [PubMed]
  • Riopelle RJ. Bromocriptine and the clinical spectrum of Parkinson's disease. Can J Neurol Sci. 1987 Aug;14(3 Suppl):455–459. [PubMed]
  • Montastruc JL, Rascol O, Rascol A. A randomised controlled study of bromocriptine versus levodopa in previously untreated Parkinsonian patients: a 3 year follow-up. J Neurol Neurosurg Psychiatry. 1989 Jun;52(6):773–775. [PMC free article] [PubMed]
  • Nakanishi T, Mizuno Y, Goto I, Iwata M, Kanazawa I, Kowa H, Mannen T, Nishitani H, Ogawa N, Takahashi A, et al. A nationwide collaborative study on the long-term effects of bromocriptine in patients with Parkinson's disease. The fourth interim report. Eur Neurol. 1991;31 (Suppl 1):3–16. [PubMed]
  • Carlson JH, Bergstrom DA, Walters JR. Stimulation of both D1 and D2 dopamine receptors appears necessary for full expression of postsynaptic effects of dopamine agonists: a neurophysiological study. Brain Res. 1987 Jan 6;400(2):205–218. [PubMed]
  • Beaulieu M. Clinical importance of D-1 and D-2 receptors. Can J Neurol Sci. 1987 Aug;14(3 Suppl):402–406. [PubMed]
  • Mercuri NB, Calabresi P, Bernardi G. Physiology and pharmacology of dopamine D2-receptors: their implications in dopamine-substitute therapy for Parkinson's disease. Neurology. 1989 Aug;39(8):1106–1108. [PubMed]
  • Barbeau A, Roy M. Six-year results of treatment with levodopa plus benzerazide in Parkinson's disease. Neurology. 1976 May;26(5):399–404. [PubMed]
  • Markham CH, Diamond SG. Long-term follow-up of early dopa treatment in Parkinson's disease. Ann Neurol. 1986 Apr;19(4):365–372. [PubMed]
  • Hoehn MM. Result of chronic levodopa therapy and its modification by bromocriptine in Parkinson's disease. Acta Neurol Scand. 1985 Feb;71(2):97–106. [PubMed]
  • Rajput AH, Stern W, Laverty WH. Chronic low-dose levodopa therapy in Parkinson's disease: an argument for delaying levodopa therapy. Neurology. 1984 Aug;34(8):991–996. [PubMed]
  • Caraceni T, Scigliano G, Musicco M. The occurrence of motor fluctuations in parkinsonian patients treated long term with levodopa: role of early treatment and disease progression. Neurology. 1991 Mar;41(3):380–384. [PubMed]

Articles from Journal of Neurology, Neurosurgery, and Psychiatry are provided here courtesy of BMJ Group

Formats:

Related citations in PubMed

See reviews...See all...

Cited by other articles in PMC

See all...

Links

  • Cited in Books
    Cited in Books
    PubMed Central articles cited in books
  • Compound
    Compound
    PubChem Compound links
  • MedGen
    MedGen
    Related information in MedGen
  • PubMed
    PubMed
    PubMed citations for these articles
  • Substance
    Substance
    PubChem Substance links

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...